Pharma & drug development · Reference
What is the pharmaceutical industry?
The pharmaceutical industry researches, develops, manufactures and markets medicines. Its defining activity is a long research-and-development pipeline that turns scientific discoveries into approved, quality-controlled products for patients.
What the industry does
The pharmaceutical industry spans the full journey of a medicine. It begins with drug discovery — finding candidate molecules — and continues through drug development, in which candidates are tested in preclinical and clinical studies. Successful products are then manufactured under Good Manufacturing Practice and marketed once approved by regulators such as the FDA. The sector includes large multinational companies, smaller biotechnology firms, generic manufacturers and a wide ecosystem of contract research and manufacturing organisations that provide specialised services.
The R&D pipeline and its economics
The industry’s central concept is the pipeline: the portfolio of candidate medicines at different stages, from early research to regulatory review. The pipeline is a metaphor for risk management, because only a fraction of projects that enter discovery reach approval. Development is long and resource-intensive, and high attrition — projects stopping when evidence is unfavourable — is an inherent feature rather than a failure. This shapes how companies invest, partner and prioritise, and explains why intellectual-property protection and pricing are recurring policy debates around the sector.
Regulation and quality
Because medicines directly affect public health, the pharmaceutical industry is among the most heavily regulated sectors. Clinical research is conducted to Good Clinical Practice, manufacturing follows GMP, and a dedicated regulatory affairs function manages the relationship with agencies across a product’s lifecycle. After approval, companies operate pharmacovigilance systems to monitor safety in real-world use. This dense web of standards is what allows the industry to translate research into products that patients and clinicians can trust.
Key facts
At a glance
- Definition: Sector that researches, develops and makes medicines
- Pipeline: Portfolio of candidates across development stages
- Players: Big pharma, biotech, generics, CROs and CMOs
- Attrition: Most candidates do not reach approval
- Regulated by: FDA, EMA, MHRA and other agencies
- Quality: GCP for trials, GMP for manufacturing
Common questions
FAQ
What is the pharmaceutical industry?+
It is the sector of companies and organisations that discover, develop, manufacture and market medicines. Its defining feature is a long, tightly regulated research-and-development pipeline. This is an educational overview, not investment or medical advice.
What is a drug pipeline?+
A pipeline is the set of candidate medicines a company or the wider industry has in development, arranged by stage from early discovery to regulatory review. It conveys both potential and risk, because many candidates stop before reaching the market.
Why is drug development so expensive?+
Development is long, scientifically uncertain and heavily regulated, and most candidates fail before approval. The cost of the successes therefore has to cover the many projects that did not make it, which is a structural feature of the industry.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
